Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Lactobacillus Rhamnosus R0011 Treatment Enhanced Efficacy of Capecitabine Against Colon Cancer in Male Balb/C Mice Publisher Pubmed



Rahimpour M1 ; Ashabi G1, 2 ; Rahimi AM3 ; Halimi S4 ; Panahi M5 ; Alemrajabi M6 ; Nabavizadeh F1, 2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Physiology, Medical School, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Electrophysiology Research Center, Neurosciences Institute, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Department of Physiology, School of Medicine, Alberoni University, Kohestan, Afghanistan
  4. 4. Department of Microbiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  5. 5. Department of Pathology, Firoozgar Hospital, Iran University of Medical Sciences, Tehran, Iran
  6. 6. Department of Surgery, Firoozgar Hospital, Firoozgar Clinical Research Development Center (FCRDC), Iran University of Medical Sciences, Tehran, Iran

Source: Nutrition and Cancer Published:2022


Abstract

The microbiome of the intestinal system is well-known as a modulatory factor. Having a balanced status of microbiota could help to prevent diseases, especially cancers related to the gastrointestinal system. We investigated the effects of Lactobacillus rhamnosus (Lr) and capecitabine on tumor size and physiologic features, such as bodyweight, liver enzymes, and blood profile, in a subcutaneously induced cancer model using CT-26 murine colon carcinoma cells. We divided 48 male Balb/c inbred mice into six groups. Lr had been orally pre-inoculated to the mice for 14 day consecutively. CT-26 cells were implanted subcutaneously into the mice’s flank. Following the injection of cancer cells, Lr was inoculated to the mice three times per week for four weeks. Capecitabine was inoculated in the third week after the induction of cancer. The tumor size was significantly decreased in treated groups in comparison to the cancer group (1174.5 ± 63.8, 1119.2 ± 86.3, and 985.6 ± 48 mm3 vs. 1674.2 ± 66 mm3, P < 0.0001). Data showed that Lr and capecitabine enhanced Bax/Bcl-2 ratio and caspase-3 level compared to cancer group (p < 0.0001). White blood cells (WBCs) were significantly decreased in the capecitabine group compared to probiotic group (P < 0.05). Measurement of bodyweight, liver enzymes, and interleukin-6 (IL-6) level showed that Lr, in addition to preventive and therapeutic effects, might have protective effects against chemotherapy side effects. Preventing WBCs’ reduction, protecting mice from losing weight, induction of apoptosis, and enhancing the serum level of IL-6 indicated that Lr might be associated with better management of colorectal cancer and chemotherapy side effects. © 2021 Taylor & Francis Group, LLC.
Related Docs
1. An Update on the Effects of Probiotics on Gastrointestinal Cancers, Frontiers in Pharmacology (2021)
2. Association Between Probiotics and Modulation of Gut Microbial Community Composition in Colorectal Cancer Animal Models: A Systematic Review (2010-2021), Canadian Journal of Infectious Diseases and Medical Microbiology (2023)
3. Dual Anti-Metastatic and Anti-Proliferative Activity Assessment of Two Probiotics on Hela and Ht-29 Cell Lines, Cell Journal (2016)
4. Emerging Roles of Probiotics in Prevention and Treatment of Breast Cancer: A Comprehensive Review of Their Therapeutic Potential, Nutrition and Cancer (2019)
5. Effects of Probiotic Yogurt on Serum Omentin-1, Adropin, and Nesfatin-1 Concentrations in Overweight and Obese Participants Under Low-Calorie Diet, Probiotics and Antimicrobial Proteins (2019)
6. Microbiome and Breast Cancer: New Role for an Ancient Population, Frontiers in Oncology (2020)
Experts (# of related papers)
View all Related Experts
Mohammad Reza Khorramizadeh (1)
Mohammad Hossein Modarressi (1)